Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo

Journal of Hepatology

Volumn 56, Issue 1, 2012, Pages 176-183

  Shao, Huanjie ^a   Gao, Chun ^a   Tang, Haikuo ^a,b   Zhang, Hao ^a   Roberts, Lewis R ^c   Hylander, Bonnie L ^a   Repasky, Elizabeth A ^a   Ma, Wen W ^a   Qiu, Jingxin ^a   Adjei, Alex A ^a   Dy, Grace K ^a   Yu, Chunrong ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

Author keywords

AKT; Apoptosis; Bim; HCC; HDAC inhibitor; mTOR kinase inhibitor

Indexed keywords

AZD 8055; BIM PROTEIN; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OSI 027; PANOBINOSTAT; PP 242; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SCID MOUSE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL DEATH; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, SCID; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 83555161682     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2011.07.013     Document Type: Article

References (37)

1. J. Bruix, L. Boix, M. Sala, and J.M. Llovet Focus on hepatocellular carcinoma Cancer Cell 5 2004 215 219 (Pubitemid 38402113)
2. L. Roberts, and G. Gores Hepatocellular carcinoma: molecular pathways and new therapeutic targets Semin Liver Dis 25 2005 212 225 (Pubitemid 40781073)
3. M. Ikeda, T. Okusaka, and H. Ueno A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma Cancer 103 2005 756 762 (Pubitemid 40216404)
4. D. Fingar, and J. Blenis Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression Oncogene 23 2004 3151 3171 (Pubitemid 38638827)
5. C. Proud mTORC1 signalling and mRNA translation Biochem Soc Trans 37 2009 227 231
6. D. Ruggero, L. Montanaro, L. Ma, and W. Xu The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis Nat Med 10 2004 484 486 (Pubitemid 38667906)
7. D. Sarbassov, D. Guertin, S. Ali, and D. Sabatini Phosphorylation and regulation of Akt/PKB by the Rictor-mTOR complex Science 307 2005 1098 1101 (Pubitemid 40262113)
8. A. Villanueva, D. Chiang, P. Newell, and J. Peix Pivotal role of mTOR signaling in hepatocellular carcinoma Gastroenterology 135 2008 1972 1983
9. J. Llovet, and J. Bruix Molecular targeted therapies in hepatocellular carcinoma Hepatology 48 2008 1312 1327
10. D. Semela, A.C. Piguet, M. Kolev, and K. Schmitter Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma J Hepatol 46 2007 840 848 (Pubitemid 46529039)
11. X. Wan, B. Harkavy, N. Shen, P. Grohar, and L. Helman Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 2007 1932 1940 (Pubitemid 46474636)
12. A. Choo, S. Yoon, and S. kim Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell type-specific repression of mRNA translation Proc Natl Acad Sci USA 105 2008 17414 17419
13. T. Phung, K. Ziv, D. Dabydeen, and G. Eyiah-Mensah Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin Cancer Cell 10 2006 159 170 (Pubitemid 44175906)
14. Y. Zhao, J. Tan, L. Zhuang, X. Jiang, E.T. Liu, and Q. Yu Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim Proc Natl Acad Sci USA 102 2005 16090 16095 (Pubitemid 41552872)
15. S. Emanuele, M. Lauricella, D. Carlisi, B. Vassallo, A. D'Anneo, and P. Di Fazio SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib Apoptosis 12 2007 1327 1338 (Pubitemid 46890392)
16. C. Nishioka, T. Ikezoe, and J. Yang Blockage of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells Leukemia 22 2008 2159 2168
17. M. Gupta, S. Ansell, and A. Novak Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2 Blood 14 2009 2926 2935
18. N. Carayola, E. Vakanaa, A. Sassanoa, and S. Kaura Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells Proc Natl Acad Sci USA 107 2010 12469 12474
19. C. Chresta, B. Davies, and I. Hickson AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity Cancer Res 70 2010 288 298
20. M. Feldman, B. Apsel, and A. Uotila Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2 PLoS Biol 7 2009 e38
21. M. Janes, J. Limon, L. So, and J. Chen Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor Nat Med 16 2010 205 213
22. C. Yu, M. Rahmani, and D. Conrad The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571 Blood 102 2003 3765 3774 (Pubitemid 37409399)
23. T. Hou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
24. J. Copp, G. Manning, and T. Hunter TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2 Cancer Res 69 2009 1821 1827
25. D. Alessi, M. Deak, and A. Casamayor 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase Curr Biol 7 1997 776 789 (Pubitemid 27441832)
26. D.A. Guertin, D.M. Stevens, and C.C. Thoreen Ablation in mice of the mTORC components raptor, Rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1 Dev Cell 11 2006 859 871 (Pubitemid 44804279)
27. A. Brunet, A. Bonni, and M.J. Zigmond Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor Cell 96 1999 857 868 (Pubitemid 29165088)
28. S. Whittaker, R. Marais, and A.X. Zhu The role of signaling pathways in the development and treatment of hepatocellular carcinoma Oncogene 29 2010 4989 5005
29. N. Oshiro, K. Yoshino, S. Hidayat, and C. Tokunaga Dissociation of raptor from mTOR is a mechanism of rapamycin-induced inhibition of mTOR function Genes Cells 9 2004 359 366 (Pubitemid 38514871)
30. K. Nakanishi, M. Sakamoto, and S. Yamasaki Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma Cancer 103 2005 307 312 (Pubitemid 40129290)
31. S. Lang, C. Moser, S. Fichnter-Feigl, and P. Schanchtschneider Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice Hepatology 49 2009 523 532
32. D. Cirstea, T. Hideshima, and S. Rodig Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma Mol Cancer Ther 9 2010 963 975
33. N. Kawamata, J. Chen, and P. Koeffler Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells Blood 110 2007 2667 2673 (Pubitemid 47523191)
34. K. Jin, L. Teng, and Y. Shen Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review Clin Transl Oncol 12 2010 473 480
35. B. Firestone The challenge of selecting the 'right' in vivo oncology pharmacology model Curr Opin Pharmacol 10 2010 391 396
36. T. Naka, B. Hylander, M. Widmer, Y. Rustum, and E. Repasky The effects of TRAIL alone and in combination with chemotherapeutic agents of a patient's colon tumor grown in SCID mice Cancer Res 62 2002 5800 5806 (Pubitemid 35204738)
37. B. Hylander, R. Pitoniak, R. Penetrante, and J. Gibbs The anti-tumor effect of Apo2L/TRAIL on patient pancreatic adenocarcinomas grown as xenografts in SCID mice J Transl Med 3 2005 22